Skip to main content

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Corrona Inflammatory Bowel Disease (IBD) Registry

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Corrona Inflammatory Bowel Disease (IBD) Registry

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Electronic Patient Reporting of Symptoms During Cancer Treatment

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Electronic Patient Reporting of Symptoms During Cancer Treatment

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 228
  • Page 229
  • Page 230
  • Page 231
  • Page 232
  • Page 233
  • Page 234
  • Page 235
  • Page 236
  • …
  • Next page Next
  • Last page Last
Subscribe to